This study focuses on people with Crohn’s Disease, which is a long-term inflammatory condition affecting the digestive system. The study will evaluate a medication called upadacitinib (also known as ABT-494), which is taken as a modified-release tablet by mouth. The purpose is to observe how well this medication works and how safe it is when used for an extended period in people who have already completed a previous study of the same treatment.

The medication will be given as a daily dose of either 15 mg or 30 mg for up to 96 months (8 years). During the study, researchers will monitor how well the treatment controls the symptoms of Crohn’s Disease, including improvements in digestive system inflammation, reduction in abdominal pain, and changes in bowel movements. They will also track how many participants are able to stop using steroid medications.

Throughout the study, participants will have regular check-ups to monitor their health and assess how well the treatment is working. The study will look at various aspects of the disease, including quality of life, ability to work, and any hospital visits related to Crohn’s Disease. Researchers will also keep track of any side effects that may occur during the long-term use of the medication.